Shaperon Inc

Shaperon Inc exhibits a highly liquid capital structure, with a current ratio of 12.53, indicating strong short-term liquidity. The company holds KRW 8,648,207,500 in cash and equivalents, which is significantly higher than its short-term liabilities. However, the company's operating cash flow is negative at KRW -14,672,489,470, and its free cash flow is also negative at KRW -14,762,306,910, suggesting ongoing operational cash outflows. Profitability metrics are severely negative, with a return on equity of -62.75% and a return on assets of -55.7%. These figures are well below the typical thresholds for biotechnology firms, which often trade at higher multiples due to growth potential. The company's operating income is negative at KRW -15,610,411,940, and its net income is also negative at KRW -15,527,830,200, indicating a lack of profitability in the most recent reporting period. The company's revenue is concentrated in its biopharmaceutical business, with no disclosed segment breakdown. Geographically, the company is based in South Korea, and there is no indication of significant international revenue diversification. This concentration may expose the company to regional economic and regulatory risks. Growth trajectory appears to be under pressure, with no disclosed revenue growth in the most recent period. The company's capital expenditures are negative at KRW -404,766,890, suggesting a reduction in investment in long-term assets. This may indicate a strategic shift or financial constraints limiting expansion. Risk factors include low liquidity and the potential for dilution, although no immediate filing-based flags were detected. The company's debt-to-equity ratio is 0.01, indicating a conservative capital structure with minimal leverage. However, the negative operating and free cash flows suggest potential liquidity challenges in the future if the company's financial performance does not improve. Recent events include the latest financial filing, which shows a continuation of negative financial performance. There are no disclosed recent events such as major product launches, regulatory approvals, or significant partnerships that could signal a turnaround in the company's fortunes.